In Brief: Guidant
This article was originally published in The Gray Sheet
Guidant: Receives expanded FDA approval of its balloon dilatation catheters for use in performing angioplasty during heart attacks, the firm says in a June 5 release. The expanded labeling is based on data from the Global Use of Strategies to Open Occluded Arteries II (GUSTO IIb) sub-study which was published in the June 5 New England Journal of Medicine. The study, by Stephen Ellis, MD, Cleveland Clinic, Ohio, et al., showed that balloon angioplasty "provides a small-to-moderate, short-term clinical advantage over thromboloytic therapy" with recombinant tissue plasminogen activator...
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.